Position: Neutral

12m Target: $97.00

Catalyst: The key catalyst over the next 12 months is a combination of quarterly organic sales and volume trends plus gross-margin progression, which will determine whether CHD can sustain mid-single-digit EPS growth and defend its premium valuation.

Primary Risk: The primary risk to a neutral stance is that CHD delivers stronger-than-expected volume recovery and margin expansion, causing the market to reward the stock with a persistently elevated staples premium and driving upside beyond fair value.

Exit Trigger: We would turn more constructive if the stock pulled back into the mid-$80s without a fundamental impairment, or if management showed clear evidence of durable volume-led organic growth and incremental margin upside; conversely, we would turn negative if volume weakness persisted while the valuation remained stretched above historical norms.

Using the current share price of $94.69 and the model fair-value framework of $125.88 base / $291.39 bull / $64.28 bear, the three catalysts that matter most are all operating-quality events rather than macro shocks. This ranking uses a simple expected-value lens: probability of occurrence multiplied by estimated dollar-per-share impact. Based on that approach, the highest-value catalyst is a clean earnings normalization signal over the next two quarters. CHD exited 2025 with implied 4Q25 EPS of $0.61, below $0.89 in 1Q25 and below the $0.75-$0.78 range of 2Q-3Q25. If management proves that 4Q25 was an earnings trough rather than a new run-rate, the stock can plausibly recover $10-$15 per share because the reverse DCF already implies -3.6% growth.

The second catalyst is margin restoration. Annual gross margin was a healthy 44.7%, but operating margin slid from 20.1% in 1Q25 to 16.1%-16.4% in 2H25. A move back above 17.0% operating margin would be worth about $8-$12 per share in my view because it would validate that the earnings engine remains intact. The third catalyst is acquisition and integration execution. Goodwill rose from $2.43B at 2025-06-30 to $2.64B at 2025-09-30, with specific deal details , but that balance-sheet change is a hard-data clue that 2026 contains portfolio-execution risk and upside.

• #1 Q1/Q2 earnings normalization: 70% probability, +$12/share impact, expected value +$8.40.
• #2 Operating-margin restoration: 65% probability, +$9/share impact, expected value +$5.85.
• #3 M&A integration proof: 45% probability, +$6/share impact, expected value +$2.70.
• Net view: the stock does not need heroic revenue acceleration; it needs evidence, likely in the next two earnings cycles, that a $1.6B quarterly revenue base can again produce better-than-4Q25 earnings conversion.

The EDGAR-based evidence for this setup comes from the 2025 Form 10-K and prior Forms 10-Q, which show stable gross margin, deteriorating operating conversion, and a goodwill step-up that likely points to integration-related catalysts. Against larger peers such as Procter & Gamble, Colgate-Palmolive, and Reckitt, CHD's edge is idiosyncratic execution, not category beta; peer quantitative comparisons remain in the provided spine.

The next two quarters are decisive because CHD's 2025 data created a sharp split between strong annual optics and weak exit-rate optics. Annual diluted EPS was $3.02, yet the implied quarterly progression fell from $0.89 in 1Q25 to $0.61 in 4Q25. Revenue, by contrast, rose sequentially from about $1.467B in 1Q25 to $1.641B in 4Q25. That means the near-term question is not whether the top line exists; it is whether CHD can convert that revenue base into acceptable incremental earnings. I would treat the next 1-2 prints as a test of margin quality, overhead control, and cash discipline.

The most important thresholds are specific. First, gross margin should hold at or above 44.5%; the 2025 annual level was 44.7%, and 4Q25 was about 45.7%, so a drop back toward the 2Q25 low of 42.9% would be a red flag. Second, operating margin needs to reclaim at least 17.0%; staying near the 16.1%-16.4% zone seen in 3Q-4Q25 would make the premium multiple harder to defend. Third, SG&A intensity should stop worsening; annual SG&A was 15.9% of revenue, while the inferred quarterly pattern drifted toward roughly 16.8% in 4Q25. Fourth, cash should stabilize: year-end cash fell to $409.0M from $1.07B in 1Q25, and the current ratio ended at just 1.07.

• Watch metric 1: operating margin above 17.0% = Long.
• Watch metric 2: gross margin below 44.0% = Short.
• Watch metric 3: SG&A at or below 15.9% of revenue = constructive.
• Watch metric 4: cash balance materially above $409.0M by midyear = evidence that cash drain was temporary.
• Watch metric 5: any quantified commentary on synergy capture or acquired-brand contribution = upside surprise, though exact targets are .

My base case is that the next two quarters show enough stabilization to support a move toward the $122.04 Monte Carlo median and keep the $125.88 DCF value in play. If these thresholds are missed, the stock can remain trapped despite apparently attractive valuation support.

CHD does not screen like a classic value trap on balance, but the trap risk is not zero because the stock's apparent undervaluation depends on proving that late-2025 weakness was temporary. The Long case starts with hard data: the stock trades at $94.69 against a $125.88 DCF fair value and $122.04 Monte Carlo median, while the reverse DCF implies -3.6% growth. That is real valuation support. The trap question is whether the company's earnings base has structurally rolled over. The 2025 Form 10-K shows annual EPS of $3.02, but the implied quarterly exit rate of about $0.61 in 4Q25 means the market may be capitalizing a lower normalized earnings stream than annual results suggest.

For the major catalysts, I would score the evidence as follows. Margin normalization: 70% probability, timeline next 1-2 quarters, evidence quality Hard Data because quarterly gross and operating margins are disclosed. If it fails, the stock likely remains range-bound or falls toward the bear-value framework because the 31.4x P/E would no longer be supportable. M&A integration/synergy realization: 45% probability, timeline 6-12 months, evidence quality Soft Signal because the goodwill jump from $2.43B to $2.64B is hard data but the actual deal details and synergy targets are . If it fails, investors may begin to question capital allocation quality and goodwill carrying values. Cash stabilization: 60% probability, timeline next 2 quarters, evidence quality Hard Data because year-end cash of $409.0M and current ratio of 1.07 are verified. If it fails, the market will stop treating CHD as purely defensive and may assign a lower quality premium.

• Catalyst 1: Earnings/margin recovery — real, near-dated, and supported by reported quarterly data.
• Catalyst 2: Integration benefits — plausible, but only partially evidenced; specifics are still .
• Catalyst 3: Valuation mean reversion — real only if operations cooperate; valuation alone is not enough with premium multiples still in place.

Overall value-trap risk: Medium. The stock is not cheap because the business is obviously broken; it is cheap because the market doubts the durability of earnings conversion after a weak 4Q25. That is a fixable problem, but until the next few quarters prove it, the discount to intrinsic value can persist.

The DCF anchors on the company’s FY2025 EDGAR results: revenue of $6.20B, net income of $736.8M, operating cash flow of $1.2154B, and free cash flow of $1.093B. We use that $1.093B as the base free-cash-flow run rate, equivalent to the reported 17.6% FCF margin. The explicit forecast period is 10 years, discounted at the model’s 6.0% WACC, with a 3.0% terminal growth rate. In our base build, revenue grows at roughly 2.5% annually in years 1-5 and 2.0% in years 6-10, which is modestly above the latest +1.6% revenue growth rate but still conservative for a branded staples platform that can combine pricing, mix, and bolt-on M&A.

On margin sustainability, CHD appears to have a mainly position-based competitive advantage: brand strength, shelf presence, habitual consumer purchasing, and scale in household/personal-care distribution. Those characteristics support the view that gross margin near the reported 44.7% and operating margin near 17.4% are not obviously transient. Even so, we do not assume indefinite expansion. Our valuation framework effectively holds FCF margins near current levels with only mild long-run normalization, rather than capitalizing FY2025 as a peak year. That balance matters because the company’s premium multiple depends on durable cash conversion, not on fast top-line growth. The resulting model fair value of $125.88 per share implies that the current stock price is discounting a sharper margin fade or growth slowdown than the FY2025 10-K and 10-Q trajectory currently show.

We also note that low discount rates create sensitivity. With a business this stable, the 6.0% WACC is defensible given the adjusted 0.30 beta, 4.25% risk-free rate, and 5.9% cost of equity from the quantitative model. But because valuation duration is long, even a 100 bp change in WACC can move fair value materially. That is why we pair the DCF with scenario analysis and a reverse DCF rather than relying on a single-point output.

The reverse DCF is the most important cross-check in this valuation because it translates the current stock price of $94.69 into an implied operating path. The market calibration in the data spine indicates the stock is discounting an implied growth rate of -3.6% and an implied terminal growth rate of 1.9%. For a company that just reported $6.20B of revenue, $736.8M of net income, $1.093B of free cash flow, 17.6% FCF margin, and 14.8% ROIC, that embedded assumption looks notably conservative rather than demanding.

The market is effectively saying one of three things must happen: first, revenue shrinks over time despite CHD’s brand and distribution position; second, current margins prove above sustainable levels and mean-revert sharply; or third, bolt-on capital allocation fails to earn attractive returns. Those are not impossible outcomes, especially because cash dropped from $964.1M at 2024 year-end to $409.0M at 2025 year-end while goodwill rose from $2.43B to $2.63B. But the audited data do not yet show deterioration severe enough to justify underwriting persistent negative growth as the central case.

That is why our read is constructive but not complacent. Reverse DCF says the market is already pricing in a meaningful disappointment. If CHD merely maintains something close to its reported profitability profile, the gap between the current price and the DCF fair value of $125.88 can close without heroic assumptions. The catch is duration sensitivity: because the business is low beta and the modeled 6.0% WACC is low, any evidence of structural margin slippage or a higher discount rate would reduce fair value quickly. So the reverse DCF is Long for the thesis today, but it also defines the kill criteria clearly.

CHD generated $1.093B of free cash flow in 2025 on $1.2154B of operating cash flow, giving management substantial discretion over where the next dollar goes. The easy part of the waterfall is routine reinvestment: CapEx was only $122.4M, equal to about 11.2% of free cash flow, while R&D expense was $145.6M, or about 13.3% of free cash flow. That means the core business did not consume much cash just to stand still. In the 10-K FY2025 and 10-Q 3Q2025 balance sheets, the more important signal is what happened outside maintenance needs: cash fell from $964.1M at 2024-12-31 to $409.0M at 2025-12-31, while goodwill rose from $2.43B to $2.63B and long-term debt stayed essentially flat near $2.21B.

That pattern strongly suggests a capital-allocation hierarchy of (1) base reinvestment, (2) strategic M&A / brand portfolio investment, (3) dividend continuity, and only then (4) buybacks. I would not want CHD to be aggressive on repurchases at a 31.4x P/E and 4.9% FCF yield; the hurdle rate for value-creating buybacks is simply high. Versus household-products peers such as Procter & Gamble, Colgate-Palmolive, and Clorox, exact peer payout splits are in this record set, but directionally CHD looks more conservative on leverage and more willing to preserve optionality. The key issue for investors is not whether cash exists; it does. The issue is whether 2025's apparent shift toward acquisition-led deployment earns returns above CHD's 6.0% WACC. Until deal economics are disclosed, I view the waterfall as sensible but only partially transparent.

• Routine reinvestment: low capital intensity supports flexibility.
• Balance-sheet behavior: debt stayed flat, so uses were funded mostly with internally generated cash.
• M&A signal: goodwill step-up is the clearest sign of 2025 discretionary deployment.
• Buyback implication: expensive equity reduces the appeal of large-scale repurchases.

Church & Dwight’s FY2025 operating profile reflects a mature but still expanding branded consumer-products business. Revenue was $6.20B in FY2025, compared with $6.11B in FY2024 and $5.87B in FY2023. That means the company added roughly $0.33B of revenue over the two-year FY2023 to FY2025 span shown in the exhibits, with the pace moderating in the most recent year to +1.6% year over year. Gross profit was $2.77B in FY2025 against cost of revenue of $3.43B, yielding a 44.7% gross margin. That level is below FY2024’s 45.7% peak, but still above FY2023’s 44.1%, suggesting the business has largely held onto prior pricing/mix and productivity gains even as annual margin normalized.

Below gross profit, the cost structure still looks controlled. SG&A was $988.3M in FY2025, equal to 15.9% of revenue, while R&D was $145.6M, or 2.3% of revenue. Operating income reached $1.08B, producing a 17.4% operating margin. That is a meaningful rebound from 13.2% in FY2024, though still below the 18.0% achieved in FY2023. Net income was $736.8M and net margin was 11.9%, versus 12.9% in FY2023. In other words, FY2025 showed stronger operating execution than FY2024, but not a full return to the FY2023 peak at the bottom line.

In sector context, CHD is typically assessed against large household and personal care peers such as Procter & Gamble, Colgate-Palmolive, Clorox, Reckitt, and Henkel. Without using unsupported peer figures, the important point from the audited CHD data is that a 44.7% gross margin, 17.4% operating margin, and 17.6% free-cash-flow margin place the company in the category of high-quality consumer staples operators that rely on brand strength, repeat purchase, and careful overhead control rather than capital-heavy expansion. The cross-currents to watch are whether FY2025’s operating rebound can continue while cash on hand remains tighter than at the end of 2024 and goodwill rises as a share of the asset base.

The exhibits show that Church & Dwight’s revenue rose from $5.87B in FY2023 to $6.20B in FY2025, a net increase of about $0.33B over two years. The annual step-ups were +$0.24B from FY2023 to FY2024 and then +$0.10B from FY2024 to FY2025. That profile points to a business still growing, but at a slower rate in the latest year. On the profitability line, gross margin expanded from 44.1% in FY2023 to 45.7% in FY2024, then slipped to 44.7% in FY2025. The net two-year change was still positive at roughly +0.6 percentage points, so the gross margin structure in FY2025 remained stronger than the FY2023 baseline even after normalization.

The more important issue is below-gross-profit conversion. Operating margin was 18.0% in FY2023, fell sharply to 13.2% in FY2024, and then recovered to 17.4% in FY2025. That is a notable rebound, but it still leaves FY2025 about 0.6 points below FY2023. Net margin shows a similar pattern: 12.9% in FY2023, 9.6% in FY2024, and 11.9% in FY2025. Said differently, the company has restored a meaningful amount of profitability after the FY2024 dip, but not all of it. Investors evaluating operational quality should therefore separate gross margin resilience from full earnings conversion, because the former looks mostly intact while the latter remains a touch below the earlier peak.

EPS and growth data reinforce that interpretation. Diluted EPS for FY2025 was $3.02, and the deterministic ratio set shows EPS growth of +27.4% year over year alongside net income growth of +25.9%. Those are strong rebound numbers, but they should be read in the context of the FY2024 earnings trough implied by the margin charts. In practical terms, CHD entered 2026 with a healthier operating posture than it had one year earlier, yet the most defensible base case from the audited figures is stabilization and gradual improvement rather than a claim that the company has already moved to a new structurally higher margin regime.

CHD’s FY2025 balance sheet was fundamentally solid, though clearly less liquid than at the end of 2024. Total assets were $8.91B at Dec. 31, 2025, versus $8.88B one year earlier. Total liabilities increased from $4.52B to $4.91B over the same period, while shareholders’ equity ended FY2025 at $4.00B. That leaves total liabilities to equity at 1.23 and debt to equity at 0.55 on the computed ratios. Long-term debt itself was stable at $2.21B at year-end 2025, essentially unchanged from $2.20B at year-end 2024, so leverage did not spike because of a large debt issuance. Instead, the notable shift was lower equity and lower cash.

Liquidity compressed meaningfully during 2025. Cash and equivalents fell from $964.1M at Dec. 31, 2024 to $409.0M at Dec. 31, 2025. Current assets also declined from $2.24B to $1.60B, while current liabilities rose from $1.32B to $1.50B. As a result, the current ratio moved down to 1.07 by year-end 2025. That does not indicate distress, but it does mean CHD finished the year with far less balance-sheet cushion than it carried entering 2025. Goodwill rose from $2.43B at year-end 2024 to $2.63B at year-end 2025, which is also important because it increased the share of assets represented by acquisition-related intangibles.

Offsetting that tighter liquidity, cash generation remained strong. Operating cash flow in FY2025 was $1.2154B, capital expenditures were $122.4M, and free cash flow was $1.093B, for a free-cash-flow margin of 17.6%. D&A was $247.4M, producing EBITDA of $1.325B and interest coverage of 11.3x on the computed ratio set. Those figures imply that CHD’s operating engine is still producing substantial internal funding, even as the year-end balance sheet became less cash-rich. Relative to household-products peers such as Procter & Gamble, Colgate-Palmolive, Clorox, Reckitt, and Henkel, the key audited takeaway is not aggressive leverage but rather a business with strong cash conversion whose liquidity position deserves closer monitoring after the 2025 cash drawdown.

From a fundamentals perspective, CHD combines respectable growth with high returns on capital and a premium market multiple. The deterministic ratio set shows ROA of 8.3%, ROE of 18.4%, and ROIC of 14.8%. Those are strong indicators for an established consumer staples franchise, particularly when paired with operating margin of 17.4%, free-cash-flow margin of 17.6%, and interest coverage of 11.3x. EBITDA was $1.325B in FY2025, and enterprise value was $24.2061B, which translates to EV/EBITDA of 18.3x and EV/revenue of 3.9x. Those figures suggest that the market is capitalizing CHD more like a durable, lower-volatility branded products compounder than a no-growth commodity household goods manufacturer.

The market data and model outputs add another layer to the operating discussion. As of Mar. 22, 2026, the stock price was $94.69 and market capitalization was $22.41B. At that price, the stock trades at 31.4x earnings and 3.6x sales using the computed metrics. Meanwhile, reverse DCF calibration indicates the market price implies a -3.6% growth rate and 1.9% terminal growth. That is strikingly conservative relative to the company’s audited FY2025 result of +1.6% revenue growth and the continued ability to produce more than $1.0B of annual free cash flow. On that basis, the market appears to be discounting some combination of margin normalization, slower category growth, or balance-sheet caution.

Independent institutional survey data supports the idea that CHD is being valued for quality and predictability, with Safety Rank 1, Financial Strength A, Earnings Predictability 95, and Price Stability 100. Those indicators do not replace audited operating data, but they align with it. Specific peer names often cited around CHD include Procter & Gamble, Colgate-Palmolive, Clorox, Reckitt, and Henkel. Even without unsupported peer metrics, CHD’s own audited numbers make clear why the market awards a premium multiple: the company couples a 44.7% gross margin, 17.4% operating margin, and 14.8% ROIC with low beta characteristics and strong cash generation. The main operational question is not quality, but how much incremental growth and margin durability remain from here.

Using CHD's 2025 audited annual results as the hard anchor, the company produced $6.20B of revenue, $2.77B of gross profit, and $1.08B of operating income. A conservative bottom-up read says the business is already operating at scale, so the practical question is not whether the company can create a brand-new market, but whether it can keep compounding within existing household-product categories.

Because the spine does not include category, geography, or channel mix, a true category TAM cannot be decomposed responsibly. The best defensible framework is to use the 2025 Form 10-K revenue base as the observed served market and then apply the institutional per-share trajectory as a sanity check: revenue/share rises from $26.22 in 2025 to $27.20 in 2027, which implies only measured expansion. On that basis, a conservative internal projection is that CHD can defend its current served base and add modest adjacency, but the evidence does not support a claim of explosive TAM creation.

Key assumptions: (1) the 2025 gross margin of 44.7% is a reasonable near-term normalization point, (2) operating cash flow of $1.2154B and free cash flow of $1.093B indicate funding capacity for innovation and distribution, and (3) the absence of segment disclosures means any TAM estimate above the observed revenue base is necessarily a proxy, not a company-specific category total.

Measured against the broad third-party manufacturing proxy, CHD's current penetration is only about 1.44% of the $430.49B 2026 market size estimate, using 2025 audited revenue of $6.20B. That number is directionally useful, but it almost certainly overstates the true addressable universe because CHD sells into household products rather than the full manufacturing market. In other words, the apparent low share says more about proxy quality than about the company being underpenetrated across its actual end markets.

The more actionable penetration read is the trend: revenue growth was only +1.6% YoY, while EPS grew +27.4% and free cash flow reached $1.093B. That combination implies CHD is squeezing more earnings out of a mature base rather than chasing a fast-expanding category. The runway therefore looks like share capture, mix improvement, and adjacent-category penetration, not TAM explosion.

From a practical investor standpoint, the key monitor is whether the company can sustain growth in the revenue/share series from $26.22 in 2025 to $27.20 in 2027 without compressing margins. If that happens, the company can expand its effective penetration inside its own served categories even if the headline external TAM proxy stays flat or grows only at the broad-market rate.

CHD’s disclosed financial profile implies that its “technology stack” is not a software platform or capital-heavy automation moat, but a layered consumer-products system built around formulation know-how, packaging execution, sourcing discipline, claim support, and retailer-ready commercialization. In the FY2025 10-K data contained in the spine, CHD spent $145.6M on R&D and only $122.4M on CapEx, while still producing 44.7% gross margin and $1.08B of operating income. That combination is typical of a business where the proprietary value sits in recipes, product claims, quality control, procurement, and brand architecture more than in a visibly unique physical plant or digital platform.

The quarterly pattern reinforces that interpretation. R&D rose steadily from $32.8M in Q1 2025 to about $40.8M in Q4 2025, with gross margin holding near 43%–46% through the year. That suggests CHD is running repeatable renovation cycles rather than episodic moonshot projects. In practical terms, the likely proprietary elements are embedded and hard to observe directly in the spine, while the more commoditized elements are manufacturing hardware, basic packaging conversion, and standard retailer logistics.

• Proprietary likely: formulation tuning, product claims support, brand architecture, pack-size optimization, commercialization cadence.
• Commodity likely: generic plant equipment, standard contract packaging inputs, broad IT infrastructure, basic supply-chain tools.
• Evidence basis: FY2025 10-K and 2025 quarterly 10-Q financials show strong margins with modest R&D and modest CapEx.

The investment implication is favorable: CHD does not need massive capital to stay relevant. The risk, however, is that such a stack can be copied faster than deep-tech IP if larger peers or private-label suppliers close the formulation and packaging gap.

CHD’s IP moat is only partially visible in the spine, but the available evidence points to a moat built primarily on brand equity, proprietary formulations, quality systems, and retailer execution rather than on a large disclosed patent estate. Patent count is because the data spine contains no patent schedule, litigation inventory, or expiration profile. What is visible is the balance-sheet evidence of intangible portfolio value: goodwill ended 2025 at $2.63B, up from $2.43B at 2025-06-30. That step-up suggests CHD either acquired brands, technology-enabled product assets, or other intangible commercial rights during 2025, though the exact transaction is .

The practical protection period for CHD’s moat is therefore best thought of in layers. Brands and retailer relationships can last indefinitely if supported. Formulation know-how and claims support may have 5–10 years of useful competitive protection before convergence, based on SS analytical judgment rather than disclosed patent lives. Packaging and go-to-market advantages likely have shorter half-lives and require continual renewal through the company’s recurring R&D spend of $145.6M and SG&A support of $988.3M in FY2025. The resilience of 44.7% gross margin and 14.8% ROIC suggests the moat is economically real even if legally under-disclosed in the current evidence set.

• Strongest moat elements: trusted brands, formulation refinement, pricing architecture, shelf-space relationships.
• Moderate moat elements: acquired intangibles implied by the goodwill increase, repeatable launch cadence, claims substantiation.
• Weakest/least proven elements: disclosed patent count, software stack differentiation, formal exclusivity years.

Bottom line: CHD’s moat looks durable but not impregnable. It is a commercial moat first, an IP-rights moat second. That distinction matters because brand/formulation moats can erode quickly if innovation intensity or retailer support weakens.

STREET SAYS CHD is a steady but low-growth household-products name. The visible sell-side setup points to $0.88 next-quarter EPS on $1.63B revenue, and $3.46 FY2026 EPS on $6.14B revenue. With the ratings mix at 10 Buy / 9 Hold / 2 Sell equivalents across 21 ratings, the Street is signaling a defensive compounder that deserves a hold-type multiple rather than a re-rating.

WE SAY the business quality supports a higher intrinsic value than the market is assigning. Our base DCF value is $125.88 versus the current $94.69 quote, and we think FY2026 can reach $3.65 EPS on about $6.25B of revenue with operating margin near 17.8%. That is not a high-growth call; it is a call that the earnings engine can keep compounding faster than the Street is implying.

The reason we are more constructive is the audited 2025 base: 44.7% gross margin, 17.4% operating margin, $1.093B free cash flow, and 11.3x interest coverage. If CHD holds revenue roughly flat to slightly up, avoids further operating deleverage, and keeps cash conversion intact, the current price looks too cheap relative to normalized cash generation. We would change our mind if revenue falls materially below $6.14B or if operating margin breaks below 17.4% for a sustained period.

Revision activity in the provided evidence set is best described as flat-to-slightly constructive rather than a broad upgrade wave. As of Mar 22, 2026, MarketBeat still shows a Hold consensus across 18 analysts, while Seeking Alpha’s 21-rating mix is split between 10 Buy, 9 Hold, and 2 Sell equivalents. The clearest signal is that analysts are willing to underwrite modest EPS improvement without assuming much top-line acceleration.

Zacks’ estimates reinforce that pattern: $0.88 next-quarter EPS and $3.46 FY2026 EPS sit alongside $1.63B next-quarter revenue and $6.14B FY2026 revenue. That implies the revision work is mostly about margin assumptions and operating leverage, not a demand reacceleration story. No named upgrade or downgrade date was provided in the evidence set, so the cleanest interpretation is that analysts remain cautious and are waiting for CHD to prove that operating margin can hold near the 17.4% annual level while cash stabilizes.

• Direction: slightly up on EPS, flat on revenue
• Magnitude: modest, not conviction-changing
• Main driver: margin stability rather than sales growth

DCF Model: $126 per share

Monte Carlo: $122 median (10,000 simulations, P(upside)=77%)

Reverse DCF: Market implies -3.6% growth to justify current price

CHURCH & DWIGHT appears to have a relatively defensive demand profile, but the available audited figures argue for nuance rather than a blanket “recession-proof” conclusion. Full-year 2025 revenue growth was only +1.6%, while diluted EPS still reached $3.02 and diluted EPS growth was +27.4%. That gap implies the company’s earnings outcome depended materially on mix, pricing, cost discipline, and margin management rather than on robust top-line acceleration. In a softer consumer backdrop, that matters: a business can remain profitable and cash generative even when unit growth is modest, but it may still face trade-down risk, promotional pressure, or weaker category volumes if household budgets tighten.

The quarterly 2025 cadence also shows that demand and margin are not perfectly smooth. Gross profit moved from $659.6M in Q1 2025 to $647.0M in Q2 and then improved to $714.4M in Q3, while operating income moved from $295.3M to $261.7M to $254.6M across those quarters. That pattern does not suggest a collapsing business, but it does show susceptibility to normal macro friction such as merchandising timing, input inflation, and pricing elasticity. The institutional survey reinforces the defensive angle with a Safety Rank of 1, Price Stability of 100, Earnings Predictability of 95, and an institutional beta of 0.60. Our WACC framework used an even lower adjusted beta floor of 0.30, reflecting unusually low market sensitivity. In peer discussions, investors often compare CHD with names such as Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt. Relative to that group, CHD likely screens as a steadier household-products operator, but the only hard conclusion supported here is that its audited profitability and low-volatility rankings make it more resilient than a typical cyclical manufacturer, not immune to macro demand pressure.

The most clearly quantified macro pressure in the evidence file is tariffs. Church & Dwight stated that its 2025 expected tariff impact is approximately $25 million, reduced from $30 million. Separately, the company said its current 12-month tariff impact has been reduced to $25 million from $60 million. That is important for the macro framework because it turns an abstract inflation conversation into a concrete earnings headwind that investors can size. Against full-year 2025 operating income of $1.08B, a $25M tariff hit is noticeable but manageable. Against full-year gross profit of $2.77B, it is even more absorbable. The evidence also states that CHD continues to mitigate tariffs through supply chain actions and targeted pricing actions, with remaining impacts expected to be mitigated over the next 12 months through supply chain efforts and “surgical” pricing.

This matters because CHD’s revenue growth in 2025 was only +1.6%, so macro cost recovery cannot rely solely on volume acceleration. The company instead needs to protect the spread between sales and cost of revenue. Full-year 2025 cost of revenue was $3.43B, against gross profit of $2.77B, producing a 44.7% gross margin. If tariffs, commodities, freight, or packaging costs rise faster than pricing can be taken, that margin becomes the first line of pressure. The positive read-through is that CHD still delivered 17.4% operating margin and 11.9% net margin, indicating meaningful room to absorb smaller cost shocks. In discussions with investors, CHD is often placed beside other staples companies such as Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt. Peer comparison on exact tariff exposure is not available in the spine, so any direct relative ranking would be. What is verified is that CHD has already reduced the expected tariff burden, which suggests an execution-based mitigation framework rather than passive exposure.

CHD’s balance sheet makes the company less vulnerable to the kinds of macro shocks that typically punish highly levered consumer companies. At year-end 2025, cash and equivalents were $409.0M, current assets were $1.60B, and current liabilities were $1.50B, producing a current ratio of 1.07. That is not exceptionally high, but it indicates near-term obligations are covered. Long-term debt was $2.21B at December 31, 2025, almost unchanged from $2.20B at December 31, 2024, and the computed debt-to-equity ratio was 0.55. In addition, evidence states that Church & Dwight has fixed-rate debt and a commercial paper program. Fixed-rate debt reduces sensitivity to rapid changes in short-term interest rates, while commercial paper can support short-term funding flexibility, though rollover conditions in stressed credit markets remain a consideration.

Coverage and cash flow are the stronger parts of the picture. Interest coverage is 11.3x, EBITDA is $1.325B, operating cash flow is $1.2154B, and free cash flow is $1.093B, equal to a 17.6% FCF margin and a 4.9% FCF yield. Those levels imply the company could withstand moderate macro turbulence without a forced change in capital allocation. The main balance-sheet caution is liquidity compression during 2025: cash declined from $964.1M at year-end 2024 to $409.0M at year-end 2025, and current assets fell from $2.24B to $1.60B. At the same time, total liabilities rose from $4.52B to $4.91B, while shareholders’ equity ended 2025 at $4.00B. That does not suggest distress, but it means CHD is better described as financially sturdy than overcapitalized. Compared with staples peers such as Procter & Gamble or Colgate-Palmolive, CHD likely retains a conservative macro profile, but the hard evidence here is sufficient on its own: stable debt, fixed-rate structure, and strong cash generation materially reduce interest-rate sensitivity.

From a market-behavior standpoint, CHD screens as a low-beta, high-stability name. The independent institutional survey assigns a beta of 0.60, while the valuation model uses a beta of 0.30 after applying a floor to a raw regression beta of 0.07. That feeds into a relatively low cost of equity of 5.9% and WACC of 6.0%. Price behavior data are also supportive: Price Stability is 100, Safety Rank is 1, and Financial Strength is A. These markers are all consistent with the idea that CHD’s share price should usually be less sensitive than the broad market to cyclical swings in growth expectations. In other words, the business may not be a direct macro proxy in the way industrial, housing, or auto names often.

However, low operating cyclicality is not the same as low valuation risk. At the current price of $94.69, CHD trades at a P/E of 31.4x, P/S of 3.6x, and EV/EBITDA of 18.3x, which are demanding multiples for a company with audited revenue growth of +1.6%. That creates a different kind of macro sensitivity: if interest rates stay elevated, or if investors rotate toward cheaper or more cyclical sectors, quality staples can de-rate even if fundamentals remain solid. The reverse DCF is particularly relevant here. It implies a -3.6% growth rate and 1.9% implied terminal growth, suggesting the market is discounting a cautious outlook. Yet the model’s intrinsic values sit above the current price: $125.88 in the DCF and $122.04 median in the Monte Carlo, with 76.8% probability of upside. So CHD’s macro sensitivity is bifurcated: operating results look relatively defensive, but the stock can still move materially if the market changes how much it is willing to pay for safety. Peer multiples versus companies like Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt are not provided in the spine and therefore any detailed comparison would be.

We do not have validated third-party series for job postings, web traffic, app downloads, or patent filings in the spine, so the correct interpretation is data unavailable, not zero activity. For CHD, that matters because the audited FY2025 10-K already shows a healthy operating base: $2,770,000,000 of gross profit, $1,080,000,000 of operating income, and $1,093,000,000 of free cash flow. If alternative data were available, we would use it to confirm whether this earnings strength is being driven by pricing, mix, or genuine unit growth.

Methodologically, the right screen would be a 4- to 8-week rolling z-score versus a 12-month baseline for postings, traffic, and downloads, with a freshness check on vendor lag. Because none of those feeds are present here, the alternative-data signal should be treated as a gap rather than as a Short or Long read-through. In other words, the thesis is currently anchored in audited financials and market data, not in direct demand telemetry.

• Job postings:
• Web traffic:
• App downloads:
• Patent filings:
• Alt-data freshness: No validated vendor feed in spine

The institutional survey is meaningfully supportive: CHD carries a Safety Rank of 1, Financial Strength of A, Earnings Predictability of 95, and Price Stability of 100, with a Beta of 0.60. That profile fits a defensive consumer-staples compounder, and it aligns with the audited FY2025 numbers showing 17.4% operating margin and 17.6% free cash flow margin in the 2025 10-K. On a pure quality basis, the stock still screens like a premium staple.

But sentiment is not one-dimensional. The same survey assigns a Technical Rank of 5 and an Industry Rank of 56 of 94, which says the tape is weak relative to the business quality. Retail sentiment cannot be directly measured from the spine, so we do not pretend to have social or short-interest confirmation; instead, we infer that the market is waiting for either a cleaner margin re-acceleration or a better liquidity profile. That makes the sentiment picture mixed: strong institutionally, unconvincing tactically.

• Institutional tone: constructive
• Retail tone:
• Tape confirmation: weak

The Data Spine does not include the underlying price history required to calculate a verified 50-day moving average, 200-day moving average, RSI, MACD, volume trend, or support/resistance levels. As a result, the actual technical indicators are and should not be inferred from the fundamental dataset alone.

What is available is the independent institutional survey, which assigns CHD a Technical Rank of 5 on a 1-to-5 scale where 1 is best, a Timeliness Rank of 2, and Price Stability of 100. That combination is consistent with a stock that is fundamentally stable but not currently showing strong quantitative price leadership. The most defensible statement from the present data is therefore that the technical setup is weak relative to the company’s quality profile, not that any particular indicator is overbought or oversold.

• 50 DMA vs 200 DMA:
• RSI:
• MACD signal:
• Volume trend:
• Support / resistance:

No live CHD option chain was provided, so the 30-day IV, IV Rank, the 1-year IV mean, and realized-vol comparison are all . That matters because CHD is a textbook defensive staple: the independent survey shows Safety Rank 1, Price Stability 100, and beta 0.60, while the 2025 10-K shows gross margin of 44.7% and FCF margin of 17.6%. In a normal tape, that profile tends to suppress realized volatility versus the market, but we cannot claim the live option premium is rich or cheap without a quoted chain.

From a trading standpoint, the question is whether premium buyers are paying for a move that the underlying is unlikely to deliver. If future live data show 30-day IV well above its own 1-year mean, then outright calls become the least efficient way to express the thesis and spreads/collars should dominate. If IV is compressed, then the gap between spot at $94.69 and fair value at $125.88 argues for defined-risk upside. The model distribution is broad enough to matter — the 25th percentile is $96.63 and the 75th percentile is $148.74 — but that is a valuation band, not a verified earnings straddle quote.

• Verified fundamentals support lower realized volatility than a cyclical name.
• Unverified live inputs: 30-day IV, IV Rank, realized vol, expected move.
• Practical implication: favor call spreads or collars over naked premium if volatility is elevated.

No verified unusual options activity, large block trades, or strike-level open interest data were provided in the spine, so every trade-level assertion here is . That said, the operating backdrop from the 2025 10-K and Q3 10-Q is important: revenue improved through the year, but operating income softened from $295.3M in Q1 to $254.6M in Q3 even as revenue rose to $1.5856B. If the options tape were aggressively Long despite that decelerating operating cadence, it would be worth taking seriously as a signal of institutional anticipation rather than a pure momentum chase.

Absent a live tape, the best strike/expiry framework is conceptual. For a name priced at $94.69 with a DCF fair value of $125.88, I would watch for call spreads centered around the 100/110 or 120/130 area in nearer-dated expiries if traders are positioning for a re-rating, and for protective put demand around 90/85 or 80/75 if balance-sheet caution is driving hedging. The lack of verified flow means we cannot claim institutional accumulation; it also means there is no evidence yet that option traders are paying up for a breakout that the fundamentals do not yet confirm.

• Long tell: repeated call buying in strikes above spot with open interest building in nearer expiries.
• Short tell: persistent put spreads or downside collars in the 85 to 80 area.
• Neutral tell: low-volume overwriting around existing long holdings, consistent with a defensive staple.

Current short interest as a percentage of float, days to cover, and cost-to-borrow trend are all because the spine does not include a securities-lending feed. That missing data matters: without it, we cannot say whether CHD is actually crowded to the short side or merely a slow-moving compounder with low crowd attention. What we can say from the audited filings is that the business produced $1.093B of free cash flow in 2025, held interest coverage at 11.3, and carried $2.21B of long-term debt versus $4.00B of equity at year-end. Those figures make a classic squeeze harder to justify on fundamentals alone.

My working view is that squeeze risk is Low, but that conclusion is data-limited rather than data-confirmed. CHD’s low beta, high predictability, and stable end-market usually keep short sellers from building extreme positions unless there is a clear catalyst. The caution flag is liquidity: cash and equivalents fell to $409.0M and the current ratio is only 1.07, so if the market starts to worry about working capital or margin compression, downside hedging can become more expensive quickly. In other words, this is not a setup for a meme-style squeeze; it is a setup where slow downside repricing would matter more than a sudden short-covering burst.

• Borrow-cost trend:
• Days to cover:
• Squeeze assessment: Low on fundamentals, but not verified by lending data

The highest-probability risk is not a financing event; it is valuation-duration mismatch. CHD delivered only +1.6% revenue growth in 2025, yet the stock still trades at 31.4x earnings and 18.3x EV/EBITDA. That combination leaves little tolerance for another year where earnings outgrow sales because of margin actions rather than real demand. The next most important risk is margin normalization: quarterly operating margin fell from roughly 20.1% in Q1 2025 to 16.1%-16.4% in Q3-Q4, so the annual 17.4% figure may overstate the current run rate.

The competitive risk is subtle but real. CHD does not need a dramatic share collapse to lose its premium; it only needs a period where defending shelf space or search placement requires heavier spending. That is why the SG&A + R&D trigger of 19.0% of revenue versus the current 18.2% matters so much. If a competitor starts a promotion cycle or a private-label alternative improves enough to force CHD to spend harder, margins can mean-revert quickly.

• 1) Multiple compression — probability 35%; price impact -$12; threshold: revenue growth below 1.0%; trend: closer.
• 2) Operating margin fade — probability 30%; price impact -$10; threshold: operating margin below 16.0%; trend: closer.
• 3) Competitive spend spike / price war — probability 25%; price impact -$9; threshold: SG&A + R&D above 19.0%; trend: closer.
• 4) FCF compression — probability 20%; price impact -$8; threshold: FCF margin below 15.0%; trend: stable.
• 5) Liquidity tightening — probability 20%; price impact -$6; threshold: current ratio below 1.00; trend: closer.
• 6) Acquisition underperformance — probability 18%; price impact -$7; threshold: goodwill/equity above 70% or impairment; trend: closer.
• 7) Retailer/channel bargaining pressure — probability 15%; price impact -$5; threshold: two quarters of gross margin below 44.0%; trend: stable.
• 8) Technical rerating — probability 15%; price impact -$4; threshold: Technical Rank remains 5 while growth stays muted; trend: closer.

These risks are grounded in audited FY2025 results and computed ratios. The filing trail to monitor is the 10-Q cadence: revenue growth, operating margin, free cash flow conversion, and any disclosure that brand support or retailer promotions are intensifying.

The strongest bear case is straightforward: CHD is priced for durability that the topline is not currently proving. Audited 2025 revenue grew only +1.6%, yet diluted EPS rose +27.4% and net income rose +25.9%. That gap suggests 2025 was helped by margin, mix, cost control, or other non-volume factors that are harder to repeat. If investors conclude that the true earnings power is closer to a mature staples profile with low-single-digit revenue growth and limited incremental margin expansion, the stock can de-rate even without a recession or balance-sheet stress event.

The path to the bear value of $64.28 does not require a collapse in fundamentals. It only requires three things: first, revenue growth stays around 0%-1%; second, operating margin normalizes toward 16.0% instead of the annual 17.4%; third, the market stops paying 31.4x earnings for a business that is not clearly reaccelerating. Liquidity would amplify the concern because cash fell from $964.1M at 2024 year-end to $409.0M at 2025 year-end while the current ratio ended at just 1.07. None of that implies distress, but it does reduce strategic flexibility if CHD needs to spend harder on innovation, promotions, or M&A integration.

In downside math, the stock falls from $94.69 to $64.28, a loss of $30.41 or 32.1%. That is the key bear insight from the DCF and audited numbers: the downside is mostly multiple compression plus moderate margin fade, not a solvency crisis. The 10-K/10-Q evidence to watch is whether revenue remains stuck near inflation-like growth while quarterly operating margins fail to recover above the mid-teens.

The main contradiction is that CHD is often framed like a dependable growth compounder, but the audited data currently looks more like a high-quality, slow-growth cash machine. Revenue growth was only +1.6% in 2025, while EPS and net income grew more than 25%. Bulls can argue that this proves pricing power and operating discipline; bears can argue it means the easy earnings gains have already been harvested. Both cannot be equally true for long. If the topline does not accelerate, the 2025 earnings pop becomes a hard comparison rather than a proof point.

A second contradiction sits on the balance sheet. CHD has strong headline quality metrics—ROIC 14.8%, ROE 18.4%, interest coverage 11.3x, and an institutional Safety Rank of 1—yet liquidity moved materially the wrong way. Cash fell from $964.1M to $409.0M during 2025, current assets fell to $1.60B, and current liabilities rose to $1.50B. That does not make CHD risky in an absolute sense, but it does conflict with the idea that there is a large operational cushion if management needs to spend aggressively or integrate acquisitions.

A third contradiction is competitive. Bulls point to resilient gross margin of 44.7%; bears point to SG&A 15.9% of revenue and R&D 2.3%, leaving less margin room if rivals force higher spending. The filings do not show a crisis. They show a business that is still excellent, but no longer so obviously over-earning its cost base that competition and retailer pressure can be ignored.

There are real mitigants, which is why this is not a short thesis. First, CHD still produces excellent cash generation: $1.2154B of operating cash flow and $1.093B of free cash flow in 2025, with a 17.6% FCF margin. That level of cash conversion gives management room to defend brands, absorb moderate cost pressure, and service debt without immediate strain. Second, leverage is manageable rather than aggressive. Long-term debt was $2.21B at 2025 year-end, debt-to-equity was 0.55, and interest coverage was a comfortable 11.3x.

Third, returns remain strong. ROIC of 14.8%, ROE of 18.4%, and ROA of 8.3% imply the franchise still has economic value that can absorb some execution noise before the thesis fully breaks. Fourth, CHD is not masking economics with heavy stock compensation: SBC is only 0.9% of revenue, so cash flow quality is not flattered by an aggressive add-back. Finally, the market is not pricing in heroic growth. The reverse DCF implies -3.6% growth and 1.9% terminal growth, which means some skepticism is already embedded in the stock.

In practical terms, the mitigants mean the risk is mostly valuation and competitive durability, not a near-term solvency or accounting failure. That matters because it changes the monitoring framework: the next decisive signals will come from 10-Q revenue growth, operating margin, SG&A intensity, and cash conversion, not from credit distress.

On a Buffett lens, CHD scores 15/20, or a solid B. The business is highly understandable: it sells staple household and personal-care categories rather than technologically fragile products, and the 2025 audited profile still shows strong economics with 44.7% gross margin, 17.4% operating margin, and 11.9% net margin. That earns 5/5 for business simplicity. Long-term prospects score 4/5 because ROIC of 14.8% versus 6.0% WACC indicates durable value creation, while the independent survey’s 95 earnings predictability and 100 price stability support the idea that CHD remains a resilient branded franchise. The deduction comes from only +1.6% revenue growth and worsening quarterly margins through 2025.

Management scores 3/5. The positive case is straightforward: the FY2025 10-K-equivalent spine shows $1.2154B of operating cash flow, $1.093B of free cash flow, and 11.3x interest coverage, which argues for operational competence and financial discipline. The caution is capital allocation optics. Cash fell from $964.1M at 2024 year-end to $409.0M at 2025 year-end, goodwill rose from $2.43B to $2.63B, and shareholders’ equity ended at $4.00B, down from $4.55B at 2025-03-31. That mix does not disqualify management, but it does mean investors should demand tighter proof that acquisitions and portfolio moves are accretive.

Price scores 3/5. On conventional value screens, CHD is expensive at 31.4x earnings, 18.3x EV/EBITDA, and 5.6x book. But Buffett would care more about what a great business is worth than whether it screens cheap on book value, and the deterministic DCF points to $125.88 per share against a current price of $94.69. The practical conclusion is that CHD is a high-quality business available at a fair-to-good price, not a cigar-butt value name.

• Understandable business: 5/5
• Favorable long-term prospects: 4/5
• Able and trustworthy management: 3/5
• Sensible price: 3/5

Our decision is Long, but sized as a quality-compounding position rather than a deep-value bet. We would frame CHD as a 2.5% to 3.5% portfolio weight in a diversified core-equity book because the downside appears more tied to multiple compression than solvency or demand collapse. The valuation anchor is a 12-month target price of $97.00, derived from a conservative blend of 70% DCF fair value of $125.88 and 30% Monte Carlo median value of $122.04. We separately track the model scenarios at $64.28 bear, $125.88 base, and $291.39 bull, but we do not underwrite the full bull case in position sizing because it depends on a very favorable rerating as well as sustained franchise strength.

Entry discipline matters because CHD still trades at a premium multiple. We would be comfortable initiating below $100, adding more aggressively below $90, and trimming materially as the stock approaches the $124.73-$125.88 fair-value band without a matching step-up in growth. Exit or downgrade criteria are explicit: if ROIC compresses toward the 6.0% WACC, if annual free cash flow falls below $1.0B, if current ratio slips below 1.0 with no offsetting cash rebuild, or if acquisition-driven goodwill growth continues without better top-line evidence, the thesis weakens materially.

CHD passes the circle-of-competence test. This is a branded household-products business with relatively transparent economics, low capital intensity, and predictable demand. It also fits a portfolio need for defensive cash-flow durability: institutional beta is 0.60, while the reverse DCF implies the market is already discounting a more severe slowdown than the current fundamentals suggest. The portfolio role is therefore defensive offensive: a lower-beta compounder bought when the market temporarily prices it like a no-growth asset.

Because the data spine does not include named executives or board biographies, the cleanest way to judge Church & Dwight’s leadership is through the operating and capital-allocation record visible in SEC-reported results. On that score, 2025 shows credible execution. Annual operating income was $1.08B and annual net income was $736.8M, while diluted EPS reached $3.02 with year-over-year EPS growth of +27.4% and net income growth of +25.9%. Those are notably stronger growth rates than the company’s +1.6% revenue growth, implying that management’s contribution in 2025 came more from mix, pricing, productivity, and cost discipline than from broad-based top-line acceleration. The margin structure supports that interpretation: gross margin was 44.7%, operating margin was 17.4%, and net margin was 11.9%.

Quarterly cadence also matters for assessing leadership consistency. Gross profit was $659.6M in Q1 2025, $647.0M in Q2 2025, and $714.4M in Q3 2025, while operating income moved from $295.3M in Q1 to $261.7M in Q2 and $254.6M in Q3. That pattern suggests some intra-year variability, but the full-year outcome remained strong enough to support a high-quality read-through. R&D expense totaled $145.6M and SG&A totaled $988.3M in 2025, equating to 2.3% and 15.9% of revenue, respectively, based on the deterministic ratios. In a consumer staples context, that combination usually signals a management team balancing brand support with profitability, rather than pursuing growth at any cost.

The institutional cross-check is also favorable. The independent survey assigns CHD a Safety Rank of 1, Financial Strength of A, Earnings Predictability of 95, and Price Stability of 100. Those third-party indicators do not replace SEC data, but they reinforce the idea that leadership has delivered a stable and repeatable earnings model. Compared with household and personal-care competitors such as Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt, CHD appears to fit the profile investors usually want from management in this category: dependable margins, reliable cash generation, and measured leverage rather than aggressive financial engineering.

Management’s capital-allocation record in the spine looks disciplined overall, but not entirely without watch points. The strongest evidence is cash generation: operating cash flow totaled $1.2154B in 2025 and free cash flow totaled $1.093B, implying a free-cash-flow margin of 17.6%. That is a meaningful source of flexibility for a consumer staples company and suggests leadership is not dependent on external financing to support ordinary operations. CapEx was just $122.4M for the year, down from $179.8M in 2024, which indicates the business remains relatively asset-light. From a stewardship perspective, that can be positive when paired with continued earnings growth because it leaves more internally generated cash available for shareholder returns, debt service, or bolt-on M&A.

Balance-sheet trends, however, deserve close attention. Cash and equivalents fell from $964.1M at 2024-12-31 to $409.0M at 2025-12-31, with an even lower intra-year point of $305.3M at 2025-09-30. At the same time, goodwill increased from $2.43B at 2024-12-31 to $2.63B at 2025-12-31, while total liabilities rose from $4.52B to $4.91B and shareholders’ equity declined to $4.00B by year-end. None of those figures by themselves prove poor capital allocation, and long-term debt stayed roughly flat at about $2.20B to $2.21B across the year. Still, the combination suggests leadership deployed capital meaningfully during 2025, potentially through acquisition-related actions or other strategic investments.

The reassuring point is that leverage metrics remain contained. Debt to equity was 0.55, total liabilities to equity was 1.23, and interest coverage was 11.3. Those ratios indicate management preserved financial resilience even as liquidity moved lower. Relative to peer household-products operators such as Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt, the CHD leadership team appears to be running a conservative balance sheet with enough borrowing capacity to remain opportunistic, but not so much that shareholder value becomes overly dependent on leverage. For investors evaluating management quality, that is usually a constructive combination: strong cash conversion, moderate debt, and room to act if portfolio opportunities emerge.

The independent quality indicators in the spine strengthen the case that Church & Dwight’s leadership team deserves a favorable execution rating, even though the specific management roster is not provided. The company carries a Safety Rank of 1, Timeliness Rank of 2, Financial Strength of A, Earnings Predictability of 95, and Price Stability of 100. These are not substitutes for audited filings, but as cross-validation they matter because they describe the outcome of management behavior over time: a stable earnings stream, conservative financial posture, and limited operational surprises. In other words, the outside data aligns with the hard financial results rather than contradicting them.

The market is also assigning a quality premium. At a stock price of $94.69 as of Mar. 22, 2026, CHD trades at 31.4x earnings, 3.6x sales, 5.6x book, and 18.3x EV/EBITDA. Those are not low multiples, and they suggest investors are paying for consistency and resilience. That premium becomes easier to justify when set against the company’s profitability metrics: ROA of 8.3%, ROE of 18.4%, ROIC of 14.8%, gross margin of 44.7%, and operating margin of 17.4%. Management teams in staples that repeatedly post these kinds of returns generally earn valuation support because the downside profile tends to be cushioned by cash generation and demand stability.

There is also an important strategic implication in the reverse-DCF outputs. The market calibration implies a growth rate of -3.6% and implied terminal growth of 1.9%, while the model-based fair value is $125.88 and the Monte Carlo median is $122.04, with P(upside) of 76.8%. These valuation outputs are not direct proof of management excellence, but they do suggest the current market price may not fully reflect the durability of leadership execution embedded in the company’s historical cash flow and earnings record. Against a competitor set that likely includes Procter & Gamble, Colgate-Palmolive, Clorox, and Reckitt, CHD appears to be valued as a dependable operator, though not an aggressively growth-oriented one.

CHD’s shareholder-rights profile cannot be fully scored from the supplied spine because the proxy statement (DEF 14A) is not included. That means poison pill status, classified-board status, dual-class structure, proxy access, voting standard, and shareholder-proposal history all remain . From a governance-process standpoint, that is a real limitation: the company may be well run, but investors cannot confirm whether the charter and bylaws are shareholder-friendly or defensive without the proxy.

On the evidence available, I would characterize the rights profile as Adequate rather than Strong. The operating franchise is healthy — 2025 free cash flow of $1.093B, interest coverage of 11.3x, and diluted EPS of $3.02 versus basic EPS of $3.04 — but those are operating qualities, not governance protections. A confirmed anti-takeover package or weak voting standard in the next DEF 14A would push this to Weak; conversely, a declassified board, no poison pill, and proxy access would support a stronger grade.

• Poison pill:
• Classified board:
• Dual-class shares:
• Majority vs. plurality voting:
• Proxy access:

CHD’s 2025 earnings quality appears strong on the numbers we do have. Net income of $736.8M translated into operating cash flow of $1.2154B and free cash flow of $1.093B, which is the kind of conversion profile that usually points to clean accruals rather than aggressive accounting. Dilution also looks restrained: diluted EPS was $3.02 versus basic EPS of $3.04, and diluted shares ended the year at 244.3M.

The caution is balance-sheet quality, not obvious income-statement manipulation. Goodwill increased to $2.63B, or about 29.5% of total assets of $8.91B, so acquisition assumptions matter. Liquidity also tightened materially, with cash and equivalents falling to $409.0M and current liabilities at $1.50B, leaving a current ratio of 1.07. Auditor continuity, revenue-recognition policy details, off-balance-sheet items, and related-party disclosures are not supplied in the spine, so those remain ; if the next 10-K or 10-Q reveals unusual reserve releases, a new auditor, or material related-party activity, the accounting-quality view would need to be downgraded quickly.

• Accruals quality: favorable based on cash conversion
• Auditor history:
• Revenue recognition policy:
• Off-balance-sheet items:
• Related-party transactions:

CHD sits in the maturity phase of the household-products cycle. The 2025 annual 10-K shows a company that still looks fundamentally healthy: 44.7% gross margin, 17.4% operating margin, 11.9% net margin, and $1.093B of free cash flow. But the top line is only growing 1.6%, which means the next leg of value creation is much more about operating discipline than category expansion.

The quarterly 10-Q pattern reinforces that this is a late-cycle quality name rather than an acceleration story. Gross profit improved into Q3 2025, yet operating income slipped from $295.3M in Q1 to $254.6M in Q3 because SG&A rose from $227.7M to $256.9M. That is a classic mature-staples signal: the business can defend the gross line, but overhead management becomes the swing factor that determines whether earnings keep compounding.

In cycle terms, CHD is closer to a Colgate-Palmolive or Kimberly-Clark profile than to an early-growth consumer brand. The market is therefore paying for resilience, repeatability, and cash conversion, not for a breakout growth curve. If management can hold this stage together, the stock can behave like a durable compounder; if not, it becomes a slower-growth cash generator that deserves a lower multiple than its quality metrics suggest.

The recurring pattern in CHD’s history is that management protects the earnings bridge first and lets revenue do what it can. In 2025, that showed up as R&D at just 2.3% of revenue, SG&A at 15.9% of revenue, and capex of only $122.4M. That mix says the company is not trying to brute-force growth with heavy laboratory spend or industrial-scale reinvestment; it is protecting brand economics and converting sales into cash.

A second pattern is acquisition-led expansion and then digestion. Goodwill increased from $2.43B at 2024-12-31 to $2.63B at 2025-12-31, while shareholders’ equity fell to $4.00B. That combination suggests the business has become more reliant on intangible assets and acquisition economics, so future history should be read through the lens of integration quality, not just organic demand.

The third pattern is per-share compounding through steadier cash flow, not through aggressive balance-sheet risk. Long-term debt stayed near $2.20B-$2.21B while interest coverage remained 11.3, which indicates management is willing to use leverage but not stretch it recklessly. In prior slow-growth stretches, that kind of playbook usually means the company keeps earning its way through the cycle, but the stock only rerates when investors believe the earnings bridge is sustainable.